News and Events

Topics

  • Topcon Announces eyeRISE 2021 Virtual Symposia & Expo

    Two-Day Special Event Will Showcase The Latest Innovations in Eye CareOAKLAND, NJ – January, 2021 – Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will host a two-day virtual symposia and expo entitled eyeRISE on February 9-10, 2021.eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care.  It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops.The two-day special event will feature more than three dozen globally-renowned speakers representing 17 countries and a range of specialties.  Educational tracks are Building Clinical Confidence which includes topics focused on retina, glaucoma and imaging;  Entering New Markets which addresses the barriers to entering myopia and dry eye management; and Too Many Patients, Not Enough Time highlighting topics such as ocular telehealth and remote diagnostics.“eyeRISE will build on the success of our previous ISSOCT conferences and expand to include all facets of eye care, delivering clinical education for the retina, glaucoma and anterior segment subspecialties. The esteemed lecture panel will present their clinical findings on the latest research topics and innovation in eye care. It should prove to be a highly informative and enlightening meeting for all attendees,”Richard F. Spaide, MD, of Vitreous Retina Macula Consultants of New York, United StatesISSOCT Chairman“We are very excited to announce eyeRISE, a one-of-a-kind, ground-breaking event that will bring together some of the most recognized names in the eye care industry to discuss the latest research and trends in patient care and practice management.  In the absence of live meetings, eyeRISE provides an engaging, interactive virtual platform and offers education for a wide range of disciplines.  It features solution-focused tracks for real world clinical and business management applications.  eyeRISE is the culmination of Topcon’s unwavering commitment to support continued innovation in eye care,” stated Carolyn Evangelista, Global Director of Medical Affairs for Topcon Healthcare.“Having the opportunity to network with colleagues and learn about the latest trends and technologies in eye care is critical for today’s practitioners, particularly in light of the global pandemic. eyeRISE provides practitioners with a unique opportunity to interact with the faculty and each other and gain practical tips and clinical insights.  Given the challenges facing today’s eye care practitioners, eyeRISE represents a wonderful learning opportunity for all clinicians,” summarized faculty member Mingguang He, MD, PhD, Professor at the University of Melbourne, Australia.For more information on eyeRISE or to register for the event, please visit Eyerise2021.com.About Topcon HealthcareTopcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever- changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multimodal imaging, vendor-neutral data management, safe distancing and ground-breaking remote diagnostic technology.A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.

  • Topcon Achieves #1 Market Position in OCT Devices

    Leads the OCT Market with Innovative Multimodal TechnologyOAKLAND, NJ – October 5, 2020 – Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has achieved the #1 position in the global OCT market, as reported by Market Scope’s 2020 Ophthalmic Diagnostic Equipment Market Report.Topcon leads the global market in the OCT segment with a 27.9 percent share.Its lineup of instruments includes the versatile Maestro2 Robotic OCT and the Triton Swept Source OCT. Both devices combine fundus and OCT functionality in an easy-to-use platform.“The Maestro2 and the Triton are engineered to help ECP’s answer complex clinical questions quickly, easily, and confidently. By delivering multiple images and data points with one click of a button in a format that is easy to understand and interpret, the Maestro2 and Triton meet the demands of today’s busy practitioners. We are thrilled at the way the market has embraced this technology,” stated Greg Hoffmeyer, Director of OCT Clinical Sales for Topcon Healthcare.The versatile Maestro2 combines fundus and OCT functionality in one device.“We are very pleased to have achieved the #1 market position in OCT devices. Our team has been hard at work leveraging the latest technology to develop versatile OCT devices that enhance practice workflow and provide exceptional clinical utility. The Market Scope recognition is confirmation that our devices are being well received by ECPs and are meeting their clinical needs.”About Topcon HealthcareTopcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever- changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multimodal imaging, vendor-neutral data management, safe distancing and ground-breaking remote diagnostic technology.A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.

  • Topcon Acquires Henson Perimeter Business

    “The acquisition of the Henson range of products will provide us with the opportunity to strategically develop this area of the company’s product portfolio. With Topcon’s growing emphasis on screening and early disease detection, the Henson product range perfectly complements our global strategy. I welcome the EET team members to the Topcon Healthcare Family.”John Trefethen, Global VP of Marketing & Product Design for Topcon HealthcareAbout Topcon HealthcareTopcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever- changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multimodal imaging, vendor-neutral data management, safe distancing and ground-breaking remote diagnostic technology.A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.About Elektron Eye Technology (EET)Elektron Eye Technology (Cambridge, UK) is a subsidiary of Elektron Technology and home to spectrum of world-class fast-moving engineered product (FMEP) brands, including the Henson Perimeters and the Macular Pigment Screener (MPS II). They are the ophthalmic instruments of choice for eye care professionals involved in the screening and monitoring of glaucoma and age-related macular degeneration (AMD). Designed in partnership with respected eye care professionals, their accuracy, efficiency and ease of use ensures that they meet the needs of optometrists and ophthalmologists, as well as the patients they work with every day.

SEE MORE

News

  • Topcon acquires VISIA Imaging S.r.l, ophthalmic medical device manufacturer in Italy

    Tokyo, Japan – July 6th, 2021 - Topcon Corporation announced that it has acquired VISIA Imaging S.r.l, an ophthalmic device manufacturer headquartered in suburban Florence, Italy.VISIA Imaging S.r.l (hereinafter “VISIA”), was established in 1993 and specializes in the design, development, and manufacturing of anterior segment (cornea, crystalline lens, etc.) examination hardware and software. This acquisition enhances Topcon’s development and manufacturing capabilities of anterior segment devices and software, which complements the company’s strong portfolio of fundus imaging devices that includes fundus cameras and optical coherence tomography (OCT). The acquisition further reinforces Topcon’s position as a leading ophthalmic diagnostic device manufacturer.For many years, Topcon has been a distributor of VISIA’s technology including the CC-100 series visual acuity charts (CC-100 series), the CA-800 topographer and corneal analyzer, the MYAH biometer and corneal topographer and the Aladdin biometer. “The integration of a Japanese company and an Italian company, both with strengths in optical design, mechanical engineering, and manufacturing of medical devices, will enhance the synergies between the two companies. Both VISIA and Topcon value true reliability and innovative technology, making two companies ideal partners. I am very excited to move forward in our business together to continue producing advanced technology that benefits both patients and eye care professionals.””- commented Fumio Ohue, Managing Executive Officer of Topcon Corporations.Major VISIA products:(from the left: ALADDIN, CA-800, CC-100, MYAH)The acquisition of VISIA will enable Topcon to create additional synergies within the company’s product portfolio, expand its product offering, strengthen the Topcon Healthcare brand, and continue to grow the business. Furthermore, the acquisition gives Topcon Healthcare additional product design and development capabilities that will accelerate product development and enable the company to better meet the needs of the market.“I am so pleased that VISIA Imaging is becoming part of Topcon Healthcare and very excited for the next chapter in our long relationship. VISIA Imaging is focused on development and manufacturing of HW/SW solutions for eye care with high expertise in anterior segment. I am confident to release new beautiful products to support Topcon to become a market leader in myopia management, and to increase Topcon’s presence in cataract surgery with Premium IOL calculation”- said Alessandro Foggi, CEO VISIA Imaging S.r.lVISIA’s product portfolio helps eye care professionals diagnose and manage a number of eye health conditions including myopia. In recent years, the increase in the number of patients at risk for myopic-related eye diseases has become a global issue, and Topcon is committed to working with eye care professionals to address this eye health problem. By integrating VISIA and its products into the Topcon Healthcare portfolio, the company is better equipped to develop myopia management solutions and strengthen collaborations with companies in the myopia treatment field.[Press release information in Europe]https://www.businesswire.com/news/home/20210714005887/en/Topcon-Healthcare-Acquires-VISIA-Imaging

  • Topcon Announces the Launch of Chronos

    It is time to reinvent refraction.Update January 28, 2021Topcon launches the revolutionary Chronos, Refraction System.Topcon, a leading provider of eye care devices and software solutions for the global eye care community, announced the launch of the revolutionary Refraction System, Chronos.Topcon Chronos offers binocular autorefraction, keratometry measurements and visual acuity with subjective testing. Chronos is the single space-saving instrument that optimizes the Eye Care Professionals’ workflow.SAVE SPACEChronos combines binocular autorefraction and keratometry measurements with binocular subjective testing and visual acuity in a single instrument that occupies minimum space.Chronos reduces the number of conventional refraction lanes and additional refractometers needed.GROWChronos offers the versatility critical for growing your practice.DELEGATESightPilot™ is a guided refraction system that simplifies the exam and facilitates delegation..list .wp-block-column { padding-left: 0;}.list .wp-block-column ul { padding-left: 20px;}.wp-block-columns+.wp-block-columns { margin-top: 20px;}@media (max-width: 781px) {.wp-block-columns+.wp-block-columns { margin-top: 40px;}}(press release information in Europe)https://kommunikasjon.ntb.no/pressemelding/topcon-announces-the-european-launch-of-chronos?publisherId=90063&releaseId=17896062(press release information in the U.S.)https://www.businesswire.com/news/home/20201113005598/en/Topcon-Announces-the-US-Launch-of-Chronos*About the Chronos, Refraction SystemAbout Topcon HealthcareTopcon Healthcare is a branded eyecare business of Topcon. Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions, including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground-breaking remote diagnostic technology.

  • IDx and Topcon sign exclusive AI platform agreement for the U.S. market

    IDx, the company behind the first and only FDA-cleared autonomous AI diagnostic system, joins forces with Topcon, a pioneering ophthalmic device manufacturer, to tackle preventable blindnessUpdate October 23, 2018CORALVILLE, IA and OAKLAND, NJ, October 22, 2018 - IDx, a leading AI diagnostics company, and Topcon, one of the world’s leading ophthalmic device manufacturers, have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions in the U.S. market.The agreement grants exclusive rights to IDx in the U.S. as the only autonomous AI company permitted to sell its products with the Topcon NW400 - an easy to use, robotic fundus camera. Topcon continues to collaborate with other partners in the AI space for solutions that fall outside of this autonomous agreement.In turn, IDx has agreed to assign Topcon’s NW400 as the only robotic desktop fundus camera with less than a 55 degree field of view to be integrated with IDx-DR, an autonomous AI system that instantly detects diabetic retinopathy in fundus images.“The importance of ease of use and consistently high image quality to successfully implement autonomous AI diagnostics in the front lines of care cannot be stressed enough,” said Michael D. Abramoff, MD, PhD, founder and CEO of IDx. “Topcon is truly the innovative market leader in developing highly automated, consistent and easy to use retinal imaging systems. Together we can prevent visual loss and blindness by ensuring the safety, accessibility, and affordability of early disease detection.”Both companies have a history of innovation. IDx received FDA clearance for IDx-DR in April 2018, marking the first time the FDA has cleared an autonomous AI diagnostic system that does not require a physician to interpret images or results. Topcon introduced the first commercial back-of-the-eye spectral domain (SD) and swept source (SS) optical coherence tomography (OCT) systems and more recently announced the widely successful Maestro and Triton OCTs.“Our partnership with IDx further solidifies our position as a pioneer in the eye care business,” said Fumio Ohue, Managing Executive Officer of Topcon. “Our efforts to deliver better workflow solutions, imaging technology, and AI tools to eye care providers will be complemented by our work with IDx to bring autonomous diagnostics to a growing population of people with diabetes.”The recent FDA clearance of IDx-DR followed a clinical trial that demonstrated the autonomous AI system’s ability to safely deliver specialty-level diagnostics in primary care settings. Novice operators received minimal training on how to capture images using the Topcon NW400 and IDx-DR’s image quality AI. They successfully produced a diagnostic result 96% of the time by consistently capturing the high-quality images needed for IDx-DR to make a disease assessment.Topcon recently announced the release and class II clearance of Topcon Harmony, a diagnostic data management application with vendor-neutral connectivity that enables software providers like IDx, EHRs and third-party manufacturers to seamlessly integrate diagnostic results into one central location for eye care providers.About IDxIDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous algorithms that detect disease in medical images. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection.The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx-DR is intended for use by health care providers to automatically detect more than mild diabetic retinopathy in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400, an easy to use and highly accurate robotic fundus camera.IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. Prior to this current round, IDx had been funded by a group of private angel investors since the company’s founding in 2010.About TopconTopcon is a comprehensive ophthalmic device manufacturer within the worldwide ophthalmic community. It introduced the world’s first commercial back-of-the-eye spectral domain (SD) and swept source (SS) optical coherence tomography (OCT) systems, which have driven innovation in eye-care.More recently, Topcon Healthcare Solutions started to enhance not only its hardware but also its software solutions. To become the leader in diagnostic software, Topcon has developed a new strategic division whose primary objective is to create world-class software solutions for the eye-care industry and beyond. The company’s products enable the collection and visualization of a wide range of imaging and clinical data while providing quantitative and clinical analysis capabilities.Topcon’s software gives clinicians access to patient exam data captured from OCTs, Visual Fields, Fundus cameras, and other Topcon and third-party devices. Topcon leverages its image management software called Synergy, where practitioners gain access to DICOM and non-DICOM information stored in a central, cloud-based environment. Additionally, Topcon now provides an integrated service that connects practitioners to an extensive network of reading services to assist in the management of sight-threatening eye diseases.IDx2300 Oakdale BlvdCoralville, IA 52241Phone: 319-248-5620www.eyediagnosis.net

SEE MORE

Events

  • TODAY
  • EVENT